KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Change in Receivables (2017 - 2025)

Guardant Health's Change in Receivables history spans 9 years, with the latest figure at $22.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 2.3% year-over-year to $22.2 million; the TTM value through Dec 2025 reached $28.2 million, up 31.73%, while the annual FY2025 figure was $28.2 million, 31.73% up from the prior year.
  • Change in Receivables for Q4 2025 was $22.2 million at Guardant Health, up from -$14.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $36.9 million in Q4 2021 and bottomed at -$14.5 million in Q3 2025.
  • The 5-year median for Change in Receivables is $4.0 million (2021), against an average of $4.3 million.
  • The largest annual shift saw Change in Receivables plummeted 3038.55% in 2021 before it surged 120683.33% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $36.9 million in 2021, then crashed by 70.04% to $11.1 million in 2022, then crashed by 100.16% to -$18000.0 in 2023, then soared by 120683.33% to $21.7 million in 2024, then increased by 2.3% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Change in Receivables are $22.2 million (Q4 2025), -$14.5 million (Q3 2025), and $14.3 million (Q2 2025).